EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

Jose U Scher iD, Iain B McInnes iD, Enrique R Soriano iD, Joseph F Merola, Paul Bird iD, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S Gensler iD, Philip J Mease iD und 1 weitere

Arthritis & Rheumatology · 2026

DOI: 10.1002/art.70152 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Jose U Scher und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Psoriatic Arthritis Center and Colton Center for Autoimmunity, New York University Grossman School of Medicine, New York, N…. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Johnson & Johnson, Johnson and Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR).

Methods

Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) + golimumab (50 mg) combination therapy (n = 59) or guselkumab monotherapy (n = 32) every 4 weeks through week 20. The primary endpoint was week 24 minimal disease activity (MDA) achievement. Additional endpoints included ≥20%/50%/70% improvement in American College of Rheumatology response criteria (ACR20/50/70): improvements in psoriasis, dactylitis, and enthesitis; changes in patient‐reported physical function; and impact of screening C‐reactive protein (CRP) on MDA/ACR50 response.

Results

At baseline, participants had a median of 13 tender and 8 swollen joints and psoriatic body surface area of 3%; 23% had dactylitis. At week 24, 29% and 22% of participants achieved MDA with guselkumab + golimumab combination therapy and guselkumab monotherapy, respectively (odds ratio [OR] 1.4 [90% confidence interval 0.6–3.3]; P = 0.557); 44% and 22% achieved ACR50 (nominal P = 0.034). Participants with CRP levels ≥0.3mg/dL (intended enrollment population) receiving combination therapy (n = 40; monotherapy n = 22) had greater odds of achieving MDA (OR 12.3; nominal P = 0.025; 32% vs 5%) and ACR50 (OR 9.6; nominal P = 0.003; 55% vs 14%) at week 24. Combination therapy was associated with higher ACR20 (66% vs 44%) and ACR70 (27% vs 16%) responses and greater physical function improvements than monotherapy. Improvements in psoriasis, dactylitis, and enthesitis were similar across groups. No new safety signals and no tuberculosis/opportunistic infections occurred through week 36.

Conclusion

Although the primary endpoint was not achieved, secondary endpoints and exploratory analyses suggest that participants with TNFi‐IR PsA, particularly those with elevated CRP levels, could derive clinically meaningful benefits with guselkumab + golimumab combination therapy, with no new safety concerns, warranting further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticAntibodies, Monoclonal, HumanizedAntirheumatic AgentsAntibodies, MonoclonalHumansFemaleMaleAdultMiddle AgedDouble-Blind MethodDrug Therapy, CombinationTreatment OutcomeInjections, SubcutaneousCombined Antibody TherapeuticsC-Reactive Protein

Substanzen

golimumabAntibodies, Monoclonal, HumanizedguselkumabAntirheumatic AgentsAntibodies, MonoclonalCombined Antibody TherapeuticsC-Reactive Protein

Autor:innen und Institutionen

  • Division of Rheumatology, Psoriatic Arthritis Center and Colton Center for Autoimmunity, New York University Grossman School of Medicine, New York, New York.
  • College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Department of Dermatology and Division of Rheumatology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.
  • University of New South Wales, Randwick, New South Wales, Australia.
  • Division of Rheumatology, Department of Medicine and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Jose U Scher, Iain B McInnes, Enrique R Soriano, Paul Bird, Lianne S Gensler, Philip J Mease, Christopher T Ritchlin

Förderung

  • Johnson & Johnson
  • Johnson and Johnson

Zitieren

APA

Scher, J. U., McInnes, I. B., Soriano, E. R., Merola, J. F., Bird, P., Chandran, V., Cheng, E., Reynoso, E., Chen, W., Li, M., Gensler, L. S., Mease, P. J., & Ritchlin, C. T. (2026). Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study. Arthritis & Rheumatology. https://doi.org/10.1002/art.70152

Vancouver

Scher JU, McInnes IB, Soriano ER, Merola JF, Bird P, Chandran V, et al. Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study. Arthritis & Rheumatology. 2026. doi:10.1002/art.70152

BibTeX
@article{Scher2026,
  author = {Scher, Jose U and McInnes, Iain B and Soriano, Enrique R and Merola, Joseph F and Bird, Paul and Chandran, Vinod and Cheng, Edaire and Reynoso, Elena and Chen, Warner and Li, Maoji and Gensler, Lianne S and Mease, Philip J and Ritchlin, Christopher T},
  title = {Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.70152}
}
Kostenlos starten →